Table 1: Baseline characteristics of the patients.

Univariate Analysis Multivariate Analysis
    Female Male p p Odds Ratio 95% CI
n 138 23
Age (years) 59.3 ± 14.7 63.9 ± 11.8 0.162*
Disease duration (years) 7.7 ± 8.2 4.2 ± 2.8 0.049*
Steroid dosage (mg/d) 2.9 ± 3.1 5.0 ± 3.4 0.005* 0.124 1.189 0.954-1.482
MTX dosage (mg/w) 8.2 ± 4.0 5.8 ± 4.4 0.011* 0.118 0.866 0.724-1.037
Infliximab 50 4 0.42**
Etanercept 14 7
Adalimumab 24 6
Golimumab 6 0
Tocilizumab 28 2
Abatacept 17 3      
SDAI 22.1 ± 11.9 27.9 ± 11.7 0.036*
mHAQ 0.46 ± 0.50 0.59 ± 0.48 0.257*
HAM-D 6.2 ± 4.8 5.8 ± 4.3 0.724*
HAM-D>7 31 (22.5%) 1 (4.3%) 0.045*** 0.011 0.041 0.004-0.486
SF-36 Physical functioning 29.3 ± 17.6 25.8 ± 17.7 0.335*
Role function (physical) 31.9 ± 16.1 28.7 ± 15.6 0.385*
Pain 35.6 ± 9.1 33.2 ± 8.6 0.252*
General health perception 39.0 ± 9.1 34.8 ± 8.1 0.040*
Fatigue 43.2 ± 11.5 41.2 ± 10.9 0.426*
Social functioning 40.3 ± 14.7 36.4 ± 15.7 0.254*
Role function (emotional) 38.9 ± 16.3 33.8 ± 16.4 0.171*
Mental health 46.6 ± 11.2 39.2 ± 11.1 0.005* 0.006 0.895 0.826-0.968

Mean ± standard deviation.SDAI: Simplified Disease Activity Index.mHAQ: modified health assessment questionnaire.HAM-D: Hamilton Depression Rating Scale.SF-36: short form-36.* analysis using Student's t-test.** analysis using the χ2 test.*** analysis using the Mann-Whitney U test.